Keyword: Sun Pharmaceutical
Teva, Sun, Lupin, Strides, WuXi STA and Cambrex all have developments.
First-round winners in the #FierceMadness ad tournament are decided, with the victors advancing to compete in Round 2's field of 32.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Gilead oncology EVP Riva joins Glenmark spinoff as CEO; Biocon's biosimilar plant dinged by FDA; Shionogi licenses Akili's digital therapeutics.
Sun Pharma debuts its first TV ad for psoriasis treatment Ilumya as national TV campaigns become table stakes in the crowded psoriasis category.
Drugmakers used last weekend’s American Association of Dermatology annual meeting to trumpet new psoriasis data they hoped would give them an edge.
Sun Pharma drops to six-year low; Takeda looks to sell emerging markets products; Immunochina raises $20 million for CAR-T push.
Sun Pharma will bring distribution of its formulations in India in house after a partnership featured in a controversy that took a toll on its share prices.
A Sun distributor allegedly inked transactions worth $816 million with a firm controlled by Sun’s co-promoter Sudhir Valia.
Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.